Research programme: HIV-1-Tat derived peptides - Trizell
Alternative Names: HIV-1-Tat derived peptides research programme - TrizellLatest Information Update: 22 Mar 2007
At a glance
- Originator Ark Therapeutics
- Developer Ark Therapeutics; National Institutes of Health (USA)
- Class
- Mechanism of Action Human immunodeficiency virus tat gene product inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 22 Mar 2007 Discontinued - Preclinical for HIV infections treatment in United Kingdom (unspecified route)
- 22 Mar 2007 Discontinued - Preclinical for HIV infections treatment in USA (unspecified route)
- 28 Feb 2003 Preclinical trials in HIV infections treatment in United Kingdom (unspecified route)